Skip to main content
. 2022 Apr 30;2022:8704127. doi: 10.1155/2022/8704127

Figure 10.

Figure 10

The role of PRS gene signature in the prediction of immunotherapeutic benefits and targeted therapy. (a) Kaplan-Meier survival curves for 49 melanoma patients with high and low PRG scores in GSE91061. (b) Rate of 49 melanoma patients' clinical responses to ICI treatment in high and low PRG scores in GSE91061. (c) PRG score in 49 melanoma patients with a different ICI response status in GSE91061. (d) Lapatinib IC50 value of LGG patients between the high-risk group and low-risk group.